PF-07826390 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and renal cell carcinoma. It acts by targeting leukocyte immunoglobulin like ...

PF-07826390 is under clinical development by Pfizer and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success ...

Livewire rounded up 10 of Australia's brightest investment minds for their top growth stock picks for the year ahead.